ICT Weekly Rounds: Ebola Execution Gaps, a Midge-Borne Virus Jumps to Humans, and IDWeek Findings

From an imported Ebola-family case in Kenya to a first-ever human Shamonda virus infection in France, this week’s coverage underscores a familiar lesson for infection preventionists: preparedness on paper only matters if it holds up in practice.

Kenya’s Bundibugyo Response Puts Execution Under the Microscope

A 40-year-old man who had lived in the Democratic Republic of Congo (DRC) landed in Nairobi on October 3, tested positive for Bundibugyo virus disease, and died about 58 hours later.

As of October 20, Kenya had confirmed 9 cases, including 8 relatives and health care workers, its first secondary cases; each was already in quarantine when symptoms began. Contact tracing identified 135 contacts. The analysis argues that failures stem less from planning gaps than from execution issues, urging teams to update outdated protocols, verify after-hours access to PPE, and confirm competency through direct observation.

Shamonda Virus Reaches Humans for the First Time

French authorities reported the first known human infection with Shamonda virus, a midge-borne pathogen previously documented only in animals. The patient, severely immunodeficient and treated in Lyon, died in early October; brain complications were “very probably linked to the virus,” though its role in the death remains under investigation.

The virus has been found in farm animals in 12 countries and on the Channel Island of Jersey. Transmission route and midge species remain unconfirmed, and no second human case has been reported. For IPs, the takeaway is diagnostic awareness of unexplained severe viral disease in immunocompromised patients, along with continued One Health monitoring.

Brucellosis: 875 Hospital Diagnoses and an Open Question About Underdiagnosis

A poster presented at IDWeek 2026 analyzed National Inpatient Sample data covering about 147 million US admissions from 2017 to 2020 and identified 875 adults with a diagnosis of brucellosis, roughly 0.6 per 100,000 admissions. Odds were higher among Hispanic patients and in the South and West.

The authors noted it is unclear whether brucellosis is underdiagnosed in the US. The findings are associations, not population estimates, but they reinforce the value of a thorough exposure history, including animal contact and unpasteurized dairy.

Ghana Blood Donor Study Finds Reactive Screening Markers in 18.3%

Also from IDWeek 2026, a retrospective study of replacement blood donors at a rural hospital in Ghana found that 954 of 5,210 complete records (18.3%) had at least 1reactive marker. Treponemal screening was most common (8.1%), followed by hepatitis C (5.7%), hepatitis B (4.6%), and HIV (1.5%). Reactivity peaked at 26.4% in 2022. As a single-center study without a comparison group, it should not be read as community prevalence, but it highlights the need for confirmatory testing and linkage to care.

Long-Acting HIV Antibodies Advance Toward Phase 2b Data

TaiMed Biologics CEO Jimmy Chang, PhD, discussed investigational antibodies TMB-365 and TMB-380 at IDWeek 2026. A phase 1 study of TMB-365 in 25 people reported only mild or moderate adverse events, supporting evaluation of 8- to 12-week dosing, and a 24-week phase 2a study reported no virologic failures among completers. A 48-week phase 2b trial in 83 adults with suppression is ongoing, and efficacy has not yet been established.

Also on the Radar

Antifungal innovation: John Rex, MD, of F2G discussed investigational oral antifungal olorofim, which met noninferiority in a phase 3 invasive aspergillosis study with fewer drug-related renal adverse events, and offered career advice for first-time IDWeek attendees.